SB-012 is under clinical development by Sterna biologicals and currently in Phase II for Ulcerative Colitis. According to GlobalData, Phase II drugs for Ulcerative Colitis have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SB-012’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SB-012 is under development for the treatment of ulcerative colitis. The drug candidate is administered through intrarectal route as enema and oral route. The drug candidate is a enzymatic oligonucleotide, DNAzyme-based and which acts by targeting GATA-3.
Sterna biologicals overview
sterna biologicals is a bio pharmaceutical company that develops next generation antisense molecules. The company’s products are used for the treatment of chronic inflammatory diseases of lung, skin, and gut such as asthma, atopic dermatitis, ulcerative colitis, psoriasis and COPD. It also performs clinical trials to advance its development pipeline. Sterna biologicals’ lead compound SB010 is used for the treatment of moderate and severe Th2-driven asthma. The company also develops pipeline product SB011, a dermal drug delivery system for the treatment of atoptic dermatitis; SB020 for the treatment of ulverative colitis, and others. It develops drugs through by transcription factors in regulating underlying inflammatory mechanisms. Sterna biologicals is headquartered in Marburg, Germany.
For a complete picture of SB-012’s drug-specific PTSR and LoA scores, buy the report here.